Sermorelin

Sermorelin (Inj)

Sermorelin is a synthetic analog of growth hormone–releasing hormone (GHRH 1–29) studied for its ability to stimulate the pituitary to release endogenous growth hormone (GH). It is commonly researched in protocols targeting GH/IGF-1 axis modulation, recovery, and body-composition outcomes.

Dosing Protocols

— 5 mg Vial —

Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
Typical daily range: 200–500 mcg once daily at bedtime (gradual titration).
Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U-100 insulin syringe.
Storage: Lyophilized: refrigerate at 2–8 °C; reconstituted: refrigerate at 2–8 °C, use within 10–14 days.

Schedule: Daily subcutaneous injections at bedtime for 3–6 months.
Cycle Length: 3–6 months typical for adult research use.
Goal: Stimulate endogenous pituitary GH release to support physiologic IGF-1 levels and anabolic processes.

Frequency: Inject once daily subcutaneously at bedtime. Bedtime administration is strongly recommended because endogenous GH secretion peaks during sleep.

Phase	Dose	Syringe (U-100)
Weeks 1–2	200 mcg	12 units (0.12 mL)
Weeks 3–4	300 mcg	18 units (0.18 mL)
Weeks 5–6	400 mcg	24 units (0.24 mL)
Weeks 7–8	500 mcg	30 units (0.30 mL)

— 10 mg Vial —

Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
Typical daily range: 200–500 mcg once daily at bedtime (gradual titration).
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
Storage: Lyophilized: refrigerate at 2–8 °C; reconstituted: refrigerate at 2–8 °C, use within 10–14 days.

Schedule: Daily subcutaneous injections at bedtime for 3–6 months.
Cycle Length: 3–6 months typical for adult research use.
Goal: Stimulate endogenous pituitary GH release to support physiologic IGF-1 levels and anabolic processes.

Frequency: Inject once daily subcutaneously at bedtime.

Phase	Dose	Syringe (U-100)
Weeks 1–2	200 mcg	6 units (0.06 mL)
Weeks 3–4	300 mcg	9 units (0.09 mL)
Weeks 5–6	400 mcg	12 units (0.12 mL)
Weeks 7–8	500 mcg	15 units (0.15 mL)

Benefits

• Stimulates pulsatile endogenous GH release via GHRH receptor activation.
• May increase IGF-1 downstream over time (dose- and individual-dependent).
• Often researched for effects on body composition, recovery, and sleep quality via GH axis modulation.
• May support markers of collagen synthesis and tissue repair indirectly through GH/IGF-1 signaling.

Mechanism of Action

Sermorelin binds the GHRH receptor on anterior pituitary somatotrophs, activating adenylate cyclase and increasing cAMP, which promotes GH secretion in a physiologic pulsatile pattern. GH then stimulates hepatic and peripheral IGF-1 production and influences lipolysis, protein synthesis, and tissue remodeling.

Side Effects

Potential adverse effects reported in literature and/or anecdotally include:

• Injection-site redness/itching.
• Headache.
• Flushing.
• Transient dizziness.
• Possible water retention or tingling sensations.

Side Effect Management

• Rotate sites and use sterile technique.
• Dose at night to align with natural GH pulse (common research practice).
• If headaches or flushing occur, reduce dose and titrate slowly.
• Monitor IGF-1 if running longer protocols.

Contraindications

• Active malignancy (GH/IGF-1 axis can support tumor growth).
• Pregnancy or breastfeeding.
• Severe untreated hypothyroidism (can blunt GH response).
• Pituitary tumors or intracranial lesions without specialist oversight.

Research Citations

PubMed-linked citations for verification. Many studies are preclinical (animal/in-vitro).

1. Growth hormone–releasing hormone (GHRH) and analogs in humans: mechanisms and clinical applications (review). Endocr Rev. PubMed
2. Sermorelin (GHRH 1–29) stimulates growth hormone secretion: clinical pharmacology reports. J Clin Endocrinol Metab. PubMed
3. Physiology of GH pulsatility and implications for secretagogue therapy. Nat Rev Endocrinol. PubMed

---